A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

Sponsor
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Study ID
NCT06633783
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
  • Semaglutide — DRUG
    The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.

Study Details

The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy®.

Key Dates

Start date
Oct 30, 2024
Status verified
Jun 2024
Primary completion
May 30, 2026
Completion
Oct 30, 2026

Study Design

Enrollment
370 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide injection
    Semaglutide：0.25 mg、0.5 mg、1.0mg、1.7mg、2.4mg
  • Active Comparator: Wegovy®
    Wegovy®：0.25 mg、0.5 mg、1.0mg、1.7mg、2.4mg

Primary Outcome Measure

Change in body weight [ Time Frame: From baseline at week 0 to week 44 ]

Central Contacts

Related Studies